A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

Neurology

Volumn 52, Issue 5, 1999, Pages 1072-1074

  Sheremata, William A ^d   Vollmer, T L ^a   Stone, L A ^b   Willmer Hulme, A J ^c   Koller, M ^c  

^a YALE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c Athena Neurosciences Inc   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NATALIZUMAB; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; URINARY TRACT INFECTION; URTICARIA;

EID: 0033596831     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.5.1072     Document Type: Article

References (10)

1. Prineas JW, Barnard RO, Kwon EE, et al. Multiple sclerosis remyelination of nascent lesions. Ann Neurol 1993;33:137-151.
2. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
3. Thompson AJ, Miller DH, Youl BD, et al. Serial gadolinium enhanced MRI in relapsing remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63.
4. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HP. Serial gadolinium enhanced magnetic resonance imaging scans in patients with early relapsing-remitting multiple sclerosis; implications for clinical trials. Ann Neurol 1991;29:548-555.
5. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
6. Hartung H-P, Archelos JJ, Zielasek J, et al. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology 1995;45:S22-S32.
7. Carlos TM, Harlan JM. Leukocyte adhesion molecules. Blood 1994;84:2068-2101.
8. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies to α4β1 integrin. Nature 1992;356:63-66.
9. Kent SJ, Karlik SJ, Cannon C, et al. A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:1-10.
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.